Our Expert Network
-
From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery?
9/23/2026
We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies.
-
Is mRNA Manufacturing Overbuilt?
9/15/2026
mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.
-
Why RNA–LNP Development Needs Higher-Resolution Analytics In 2027
9/11/2026
Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential.
-
Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery
9/9/2026
We discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.
-
Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases
9/4/2026
Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.
-
RNA Oligonucleotide Synthesis: How Advanced Manufacturing Technologies Are Accelerating Innovation
9/3/2026
From a tech perspective, the manufacturing objective is shifting toward integrated process optimization. Automated reaction control, multivariate analytics, and more can connect molecular quality with operational performance.
-
AI Agents Are Only As Good As The RNA Knowledge Behind Them
9/3/2026
The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent.
-
Will 2027 See A Meteoric Rise Of Programmable Nanomedicine?
9/2/2026
The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.
-
From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2)
8/26/2026
Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.
-
Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
8/19/2026
Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.